The overall reimbursement coverage rate in New Zealand was considerably lower than the median listing rate in Canadian provincial drug plans for angiotensin-converting-enzyme inhibitors (ACEIs; 60.0% vs. 100.0%; p = 0.007), angiotensin receptor blocking (ARB) drugs (30.8% vs. 100.0%; p < 0.0001), statins (71.4% vs. 100.0%; p = 0.19), drugs for cancers other than the four major cancer types of breast, colorectal, lung and prostate (56.2% vs. 95.2%; p = 0.012), and drugs used to treat multiple types of cancer (75.0% vs. 96.9%; p = 0.026) (Table 2). This evidence concerns the gene ACE and cancer.